News | December 05, 2022
Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
40,000 visitors and representatives of more than 80 countries set to visit the show
Approval broadens indication for ENHERTU to earlier use in metastatic breast cancer and requirement for confirmatory phase 3 trial
The only definitive way to diagnose and stage lung cancers is through biopsies
Joint Drugs Controller (India) Dr PBN Prasad shared his views about working during harsh COVID-19 pandemic days
The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.
In fact, the overall CPHI Pharma Index – a collateralised metric of all major ranking categories – has risen by more than 8%, the largest year-on-year gain in the survey’s six year history
Ayush market has reached US $18 billion from meager US $3 billion under guidance and visionary leadership of our Prime Minister
Subscribe To Our Newsletter & Stay Updated
